APDN: Applied DNA Corp Growth-Adjusted Market Cap to Net Income
Applied DNA Sciences is currently in its maturity stage, developing PCR solutions for diagnostics. A team of top-tier biologists leverages a robust engineering foundation for brand protection. The PEG growth stock filter on the GURU.Markets daily price chart reflects a trend where 0.00 indicates the current level. This confirms the company's status as a leader in molecular tagging, ensuring the authenticity of raw materials in pharmaceuticals.
Analytical breakdowns for Applied DNA Sciences (APDN)
- current price and projected stock value:
- market capitalization information:
- company book value details:
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Applied DNA Sciences|APDN - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio adnas.com|APDN - Company Debts|Debt to Book Value Ratio Applied DNA|APDN - Company Long-Term Debts|Company Short-Term Debts Applied DNA Sciences|Intermediate Coverage Ratio adnas.com
- earnings and multiples data:
APDN - Company Net Income|Company Profit Forecast Applied DNA Sciences|APDN - P/E Multiple|Projected Price to Earnings Applied DNA Corp|APDN - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Applied DNA|APDN - Operating profit EBITDA|Net earnings per one share for the last twelve months Applied DNA Sciences|APDN - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months adnas.com|APDN - Earnings growth in current year|Expected earnings per share growth for next year Applied DNA Sciences
Fundamental company analysis:Applied DNA Sciences Inc (APDN)
Investments in the unique DNA R&D patents and highly qualified biological staff of Applied DNA Sciences (APDN) require an assessment of profit growth efficiency relative to market value. The PEG investment attractiveness indicator compares the P/E multiple with business expansion rates, identifying undervalued assets when the value falls below one. This chart allows investors to promptly identify imbalance points to open long positions or lock in gains from overheated positions.
Competing companies
Price/Earnings to Growth Ratio TEM (Tempus AI, Inc)|PEG Multiple QGEN (Qiagen Group)|Growth-Adjusted Market Cap to Net Income Isis Pharmaceuticals (IONS)|Repligen Corporation - PEG Multiple|Price to Earnings Adjusted for Growth Rate aviditybiosciences.com|CRSP: PEG Multiple|Growth-Adjusted P/E Ratio WGS|Price/Earnings to Growth Multiple RARE|BEAM: Growth-Adjusted Payback Ratio|PEG Multiple SRPT|twistbioscience.com - Growth-Adjusted P/E Ratio|Price/Earnings to Growth Ratio 10x Genomics TXG|NTLA: Growth-Adjusted P/E Ratio|Stoke - PEG Multiple|BLFS - PEG Multiple|WVE (Wave Life Sciences) - Price/Earnings to Growth Multiple|mazetx.com - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Sionna Therapeutics|Prime Medicine Inc (PRME) - Growth-Adjusted Market Cap to Net Income|PEG Multiple TSHA|Price/Earnings to Growth Multiple uniQure Pharma QURE|PEG Multiple MGTX (MeiraGTx Holdings plc)|Growth-Adjusted Market Cap to Net Income regenxbio.com (RGNX)|Solid Biosciences - PEG Multiple|Price to Earnings Adjusted for Growth Rate Ocugen Inc|Pacific Biosciences of California (PACB) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio BNTC|DSGN (Design Therapeutics) - PEG Multiple|Price/Earnings to Growth Multiple rocketpharma.com (RCKT)|PEG Multiple FDMT|LXEO - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Korro Bio KRRO|Growth-Adjusted Market Cap to Net Income Editas Corp (EDIT)|Silence Therapeutics - PEG Multiple|PRQR - PEG Multiple|codexis.com (CDXS) - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio SGMO (Sangamo Therapeutics Inc.)|NAUT (Nautilus Biotechnology, Inc.) - PEG Multiple|Growth-Adjusted P/E Ratio MGX (Metagenomi Therapeutics)|Price/Earnings to Growth Ratio Precision BioSciences (DTIL)|generationbio.com - Growth-Adjusted P/E Ratio|PEG Multiple BOLD (Boundless Bio)|XCUR: Growth-Adjusted P/E Ratio|IMNN - Price/Earnings to Growth Ratio|PHIO (Phio Pharmaceuticals) - Growth-Adjusted P/E Ratio|MBIO: PEG Multiple|TransCode Therapeutics, Inc. (RNAZ) - PEG Multiple|BNGO (Bionano Genomics Inc.) - PEG Multiple|PEG Multiple bluebird bio Inc.|Price/Earnings to Growth Ratio ImmunoPrecise Antibodies (IPA)|OMGA: Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Ratio Singular Genomics Systems OMIC|RGLS (regulusrx.com) - Market Cap to Earnings and Growth Ratio|SYRS - Price/Earnings to Growth Ratio|TBIO: Price/Earnings to Growth Ratio|TCON: PEG Multiple|UBX - Growth-Adjusted Market Cap to Net Income
